跳至主要内容
临床试验/NCT00657904
NCT00657904已完成3 期

A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer.

AstraZeneca1 个研究点 分布在 1 个国家目标入组 3,618 人开始时间: 1995年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
AstraZeneca
入组人数
3,618
试验地点
1
主要终点
Time to clinical progression

研究概览

简要总结

The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Prostate cancer in the early stage of disease
  • Prostate removed and/or radiation therapy to the prostate area

排除标准

  • Previous systemic therapy for prostate cancer
  • Previous history of another form of cancer (not prostate) within 5 years of study start.

研究组 & 干预措施

1

Experimental

干预措施: Bicalutamide (Drug)

2

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Time to clinical progression

时间窗: Throughout study period

Overall patient survival

时间窗: Throughout study period

次要结局

  • Time to treatment failure(Throughout study period)
  • Serum prostate-specific antigen(Initial study period up to 2006 amended protocol)
  • Tolerability in terms of adverse events and laboratory parameters(Throughout study period)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Bicalutamide (Casodex™) Versus Placebo in Patients... | 临床试验